Stay updated with breaking news from Style Libre. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Abbott (NYSE: ABT), CamDiab and Ypsomed today announced that they are partnering to develop and commercialize an integrated automated insulin delivery (AID) system to help lessen the burden of round-the-clock diabetes management for people with diabetes. The initial focus of the partnership will be in European ...
Abbott announced today that a new real-world meta-analysis provided positive data for its FreeStyle Libre system.
/PRNewswire/ -- Abbott (NYSE: ABT), CamDiab and Ypsomed today announced that they are partnering to develop and commercialize an integrated automated insulin...
/PRNewswire/ -- Abbott (NYSE: ABT), CamDiab and Ypsomed today announced that they are partnering to develop and commercialize an integrated automated insulin...
/PRNewswire/ -- Making CES history, Abbott (NYSE: ABT) presented a keynote at the most influential tech event in the world, the first healthcare company ever...